Ypsomed increases dividends to shareholders for the third time in a row
After 10 years, the general meeting of the Burgdorf-based medical engineering company was held again in the newly renovated Burgdorf market hall. All proposals of the Board of Directors were approved by the shareholders. The direc-tors, Dr. h.c. Willy Michel, Anton Kräuliger, Prof. em. Norbert Thom and Gerhart Isler, have been reelected to their offices until the next regular general meeting. Dr. h.c. Willy Michel was approved as president of the board of directors for the same period. The remuneration for the board of directors and management was accepted without discussion. The dividend payout increased for the third time in a row. Compared to the previous year, the dividend was increased by two thirds.
The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years' experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands mylife™ Diabetescare directly to patients or through pharmacies and clinics and under YDS™ Ypsomed Delivery Systems as business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs around 1'200 employees.